Uday R. Popat, MD, on the Future of Post-Transplant Cyclophosphamide to Prevent GVHD After Transplant for AML/MDS
May 27, 2022

Uday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.

Increased Overall Survival Linked With Investment in Public Welfare for Black Patients With Cancer
May 26, 2022

Patients who are black had a longer overall survival after investment was made for public welfare programs concerning those with cancer.

Despite Increased Use of Telemedicine for Cancer Care During COVID-19, Disparities Persist
May 26, 2022

The findings of this retrospective study of more than 25,000 patients with cancer newly diagnosed during the COVID-19 pandemic highlight a need to reduce the inequities in telemedicine use for cancer care, according to the study’s lead author.

Black Patients with Metastatic Breast Cancer Less Likely to Trust, Participate in Clinical Trials
May 26, 2022

A Black patient with metastatic breast cancer explained that the results of the survey show that more work must be done by all stakeholders to increase the participation in clinical trials to accurately assess treatments in diversified populations.

Despite Poor Prognosis, Anlotinib May Improve PFS in Pre-Treated NSCLC With Liver Metastases in Later Lines
May 26, 2022

The phase 3 ALTER 0303 trial demonstrated that although patients with non–small cell lung cancer and liver metastases have a worse prognosis than those without, treatment with anlotinib may result in better progression-free survival vs a placebo.

Case Presentation: A 74-Year-Old Woman with Relapsed/Refractory Multiple Myeloma
May 26, 2022

Experts discuss the case of a woman with relapsed/refractory multiple myeloma and the available treatment options, including novel BCMA-targeted agents.

Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data
May 26, 2022

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Blood-Based MRD Testing and Transplant-Ineligible Multiple Myeloma
May 26, 2022

Key opinion leaders describe the role of blood-based MRD testing in the transplant-ineligible multiple myeloma treatment landscape.

Dose Reductions and Treatment Breaks on Lenvatinib Therapy
May 26, 2022

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

Notable Economic Burden Associated With Early Discontinuation of Hypomethylating Agents in High-Risk MDS
May 26, 2022

Early discontinuation of a hypomethylating agent was associated with an increase in economic burden for those with refractory anemia with excess blasts, a diagnosis that overlaps with high-risk myelodysplastic syndrome.